Valuation : ZIM Laboratories Limited

Market Cap 7.12B 74.84M 64.32M 60.6M 55.22M 103M 104M 717M 277M 3.63B 281M 275M 11.49B P/E 2025
32.1x
P/E 2026 50.3x
Enterprise Value 7.98B 83.91M 72.11M 67.95M 61.92M 116M 116M 804M 311M 4.07B 315M 308M 12.88B EV / Sales 2025
1.34x
EV / Sales 2026 1.09x
Free-Float
28.77%
Yield 2025 *
-
Yield 2026 -
1 day+2.94%
1 week+11.82%
Current month+7.52%
1 month+18.60%
3 months+28.52%
6 months+98.88%
Current year+84.94%
1 week 125.2
Extreme 125.2
134.95
1 month 106
Extreme 106
136.8
Current year 59.72
Extreme 59.72
136.8
1 year 59.72
Extreme 59.72
136.8
3 years 59.72
Extreme 59.72
136.8
5 years 36.37
Extreme 36.366666
151.75
10 years 14
Extreme 14
151.75
Manager TitleAgeSince
Chief Executive Officer - 2001-12-31
Director of Finance/CFO - 2019-03-31
Director of Finance/CFO - 1990-12-31
Director TitleAgeSince
Chairman - 1989-12-31
Director/Board Member - 1990-12-31
Director/Board Member - 2012-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+2.94%+11.82%+76.35%+6.83% 72.95M
-1.11%-3.32%+17.96%+64.97% 47.73B
-1.06%-5.77%+37.73%+115.68% 40.21B
-1.58%-3.46%+11.66%+79.48% 12.05B
-1.51%-4.21%-11.56%+9.52% 11.79B
+0.38%-1.32%+21.40%+137.27% 9.16B
0.00%-4.04%+21.19%+33.90% 7.34B
-2.95%-5.33%+32.45%-15.96% 7.39B
-1.60%-1.43%+18.67%+213.45% 7.37B
+1.32%-1.19%-46.13%+22.77% 5.13B
Average -0.52%-0.89%+17.97%+66.79% 14.82B
Weighted average by Cap. -1.05%-2.67%+19.40%+80.27%

Financials

2025 2026
Net sales 3.79B 39.85M 34.25M 32.27M 29.41M 55.03M 55.22M 382M 148M 1.93B 150M 146M 6.12B 3.74B 39.36M 33.82M 31.87M 29.04M 54.34M 54.54M 377M 146M 1.91B 148M 145M 6.04B
Net income 122M 1.28M 1.1M 1.04M 944K 1.77M 1.77M 12.26M 4.74M 62M 4.8M 4.7M 196M 58.38M 614K 527K 497K 453K 847K 850K 5.88M 2.27M 29.75M 2.3M 2.25M 94.21M
Net Debt 1.16B 12.17M 10.46M 9.85M 8.98M 16.8M 16.86M 117M 45.08M 590M 45.68M 44.69M 1.87B 863M 9.07M 7.8M 7.35M 6.69M 12.53M 12.57M 86.95M 33.61M 440M 34.06M 33.32M 1.39B
Logo ZIM Laboratories Limited
ZIM Laboratories Limited is a pharmaceutical company. The Company develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. Its delivery solutions cover product conceptualization product development, filing for registration, manufacture, and supply of various pharmaceutical formulations. It is developing products in various therapeutic segments like, central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology and vitamins, minerals, and dietary supplements. Its technological capabilities include drug release modification, solubility and stability enhancement, taste masking and dosage form transformation. Its product offerings include finished formulations and pre-formulations intermediates, which include granules, pellets, taste-masked powders, dry suspensions, tablets, capsules, and oral thin films.
Employees
632
Date Price Change Volume
26-09-09 ₹132.95 +2.94% 7,870
26-09-08 ₹129.15 0.00% 1,834
26-09-07 ₹129.15 +2.87% 7,712
26-09-04 ₹125.55 -1.88% 15,609
26-09-03 ₹127.95 -4.23% 14,352
  1. Stock Market
  2. Stocks
  3. ZIMLAB Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!